183 related articles for article (PubMed ID: 35718073)
1. Patterns of Recurrence After Primary Local Therapy for Pancreatic Ductal Adenocarcinoma - A Critical Review of Rationale and Target Delineation for (Neo)Adjuvant Radiation Therapy.
Jethwa KR; Neibart SS; Truty MJ; Jabbour SK; Hallemeier CL
Pract Radiat Oncol; 2022; 12(6):e463-e473. PubMed ID: 35718073
[TBL] [Abstract][Full Text] [Related]
2. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
3. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
4. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
5. Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Kobayashi R; Hayami S; Ueno M; Yamaue H
Eur J Surg Oncol; 2021 Oct; 47(10):2586-2594. PubMed ID: 34127329
[TBL] [Abstract][Full Text] [Related]
6. Tenascin C in the Tumor-Nerve Microenvironment Enhances Perineural Invasion and Correlates With Locoregional Recurrence in Pancreatic Ductal Adenocarcinoma.
Furuhashi S; Sakaguchi T; Murakami T; Fukushima M; Morita Y; Ikegami K; Kikuchi H; Setou M; Takeuchi H
Pancreas; 2020 Mar; 49(3):442-454. PubMed ID: 32132519
[TBL] [Abstract][Full Text] [Related]
7. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
[TBL] [Abstract][Full Text] [Related]
8. Current State and Future Directions of Radiation Therapy for Pancreas Adenocarcinoma.
Gottumukkala S; Salamekh S; Sanford NN
Surg Oncol Clin N Am; 2023 Jul; 32(3):399-414. PubMed ID: 37182984
[TBL] [Abstract][Full Text] [Related]
9. Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.
Chatterjee D; Katz MH; Rashid A; Wang H; Iuga AC; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Crane CH; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
Am J Surg Pathol; 2012 Mar; 36(3):409-17. PubMed ID: 22301497
[TBL] [Abstract][Full Text] [Related]
10. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement.
Jolissaint JS; Reyngold M; Bassmann J; Seier KP; Gönen M; Varghese AM; Yu KH; Park W; O'Reilly EM; Balachandran VP; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Jarnagin WR; Crane CH; Wei AC
Ann Surg; 2021 Dec; 274(6):894-901. PubMed ID: 34269717
[TBL] [Abstract][Full Text] [Related]
11. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
12. Location, Location, Location: What Should be Targeted Beyond Gross Disease for Localized Pancreatic Ductal Adenocarcinoma? Proposal of a Standardized Clinical Tumor Volume for Pancreatic Ductal Adenocarcinoma of the Head: The "Triangle Volume".
Hill CS; Fu W; Hu C; Sehgal S; Reddy AV; He J; Herman JM; Meyer JJ; Zaheer A; Narang AK
Pract Radiat Oncol; 2022; 12(3):215-225. PubMed ID: 35144016
[TBL] [Abstract][Full Text] [Related]
13. Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection.
Cha DE; Yu AT; Khajoueinejad N; Gleeson E; Shaltiel T; Berger Y; Macfie R; Golas BJ; Sarpel U; Labow DM; Hiotis S; Cohen NA
World J Surg; 2023 Jul; 47(7):1801-1808. PubMed ID: 37014430
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Adjuvant Chemotherapy Survival Outcomes Among Patients With Surgically Resected Pancreatic Carcinoma With Node-Negative Disease After Neoadjuvant Therapy.
Hammad AY; Hodges JC; AlMasri S; Paniccia A; Lee KK; Bahary N; Singhi AD; Ellsworth SG; Aldakkak M; Evans DB; Tsai S; Zureikat A
JAMA Surg; 2023 Jan; 158(1):55-62. PubMed ID: 36416848
[TBL] [Abstract][Full Text] [Related]
15. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Therapy in Pancreas Cancer: Does It Influence Patterns of Recurrence?
Parikh AA; Maiga A; Bentrem D; Squires MH; Kooby DA; Maithel SK; Weber SM; Cho CS; Katz M; Martin RC; Scoggins CR; Sutton J; Ahmad SA; Abbott DE; Carr J; Kim HJ; Yakoub D; Idrees K; Merchant N
J Am Coll Surg; 2016 Apr; 222(4):448-56. PubMed ID: 26895735
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
18. Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles.
Zhu X; Cao Y; Ju X; Zhao X; Jiang L; Ye Y; Shen Y; Cao F; Qing S; Zhang H
Cancer Sci; 2021 Jan; 112(1):287-295. PubMed ID: 32418280
[TBL] [Abstract][Full Text] [Related]
19. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma.
Ye Y; Chen J; Zhou Y; Fu Z; Zhou Q; Wang Y; Gao W; Zheng S; Zhao X; Chen T; Chen R
J Transl Med; 2015 Apr; 13():137. PubMed ID: 25925763
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
